CURRICULUM VITAE
PERSONAL DATA
Barbara Anne Pickut M.D., M.P.H.
Born Canada, Kitchener, Ontario
Neurologist, Neurorevalidation physician
University Hospital Antwerp (UZA), Belgium
Guest Professor
- Artesis College of Health Sciences – Neuroanatomy - Artesis
Hogeschool/University of Antwerp, Belgium
- College of Sociology and Law – Neurology & Mindfulness
Utrecht, The Netherlands
Addresses:
University Hospital Antwerp (UZA)
Department of Neurology
Wilrijkstraat 10
2650 Edegem, Belgium
Phone: 32-(0)3-281.52.12
Artesis College of Health Sciences
Van Aertselaerstraat 31
2060 Antwerpen - Merksem
Phone: 32-(0)3-641.82.65
References: (co-) author on more than 55 published articles.
CV Barbara A. Pickut
Page 1/5
CLINICAL STUDIES AND TRIALS
#
1
2
3
4
5
6
7
8
9
10
Title
A double-blind, L-dopa plus Benserazide controlled,
multicenter study of Ropinirole at a flexible oral dose of
0.25 - 8 mg three times daily for five years in the
treatment of early Parkinsonian patients not treated
with L-dopa.
A double-blind, Bromocriptine controlled, multicenter
study of Ropinirole at a flexible oral dose of 0.25 - 8 mg
three times daily for six months in the treatment of
Parkinsonian patients not optimally controlled on Ldopa (DCI).
A double-blind, Bromocriptine controlled, multicenter
study of Ropinirole at a flexible oral dose for six months
extension in the treatment of Parkinsonian patients not
optimally controlled on L-dopa (DCI).
Double-blind, placebo-controlled, parallel-group
comparison to assess the safety, tolerance and efficacy
of Pramipexole in early Parkinson’s disease (Part I)
and to assess long term safety with open-label
Pramipexole (Part II)
A European double-blind, placebo-controlled, parallelgroup comparison to assess the safety, tolerance and
efficacy of Pramipexole in early Parkinson’s disease
(part I) and to assess long term safety with open-label
Pramipexole (Part II)
Study of Pergolide in the treatment of old Parkinson
patients.
Multinational, multicenter, randomized, double-blind,
double-dummy, parallel group study comparing TV1203/ Carbidopa dispersible tablets with
Levodopa/Carbidopa tablets in advanced Parkinson’s
disease (PD) patients with motor fluctuations. RONDO
Study.
A double blind, placebo-controlled, parallel group study
to assess the efficacy, safety and tolerability of BTS 74
398 in patients with recently diagnosed Parkinson’s
disease (PD) who are not being treated with any
medication (early untreated PD patients).
A multinational, multicenter, open label study to
evaluate the safety and tolerability of TV1203/carbidopa dispersible tablets in advanced
Parkinson’s disease (PD) patients with motor
fluctuations treated with chronic Levodopa/DDI therapy.
(RONDO extension)
Functional Improvement of Parkinsonian patients by
Optimalizing Pergolide (FIPOP). An observational
program.
A phase II, double-blind, placebo-controlled
randomized study comparing the efficacy, safety and
tolerability of Sumanirole versus placebo or Ropinirole,
as an adjuvant to Levodopa, in patients with advanced
Parkinson’s disease.
CV Barbara A. Pickut
Protocol#
Protocol
Date
101468/056
March-92
101468/043 //
101468/050
April-92
M/2730/0001
January-93
M/2730/0005 //
M/2730/0006
June-93
B4G-BX-S001
October-99
TV-1203/116
May-00
BTSPD-003
October-00
TV-1203/118
November00
B4G-UT-LCDN
FIPOP
//
666E-CNS-0075-0022
March-01
August-01
Page 2/5
11
12
13
14
15
16
17
18
19
20
21
22
23
A multicenter, multinational, phase III, randomized,
double-blind, double-dummy, 3-arm parallel group,
placebo- and Ropinirole-controlled trial of the efficacy
and safety of the Rotigotine CDS patch in subjects with
SP513
August-01
early stage idiopathic Parkinson’s disease (Part I), and
an open-label extension to assess the safety of longterm treatment of Rotigotine CDS (Part II).
An open-label, long-term, flexible-dose study of safety,
tolerability and therapeutic response of PNU-95666E in
666E-CNS-0075-0019
May-00
patients with Parkinson’s disease.
A phase III, multi-center, randomized, double-blind,
placebo-controlled, fixed dose response study
DA2APD-0075-031
May-02
comparing the efficacy and safety of Sumanirole versus
placebo in patients with early Parkinson’s Disease.
A 24-week prospective, randomized, multicenter,
double-blind, placebo-controlled, parallel group study of
the efficacy, tolerability and safety of 3-12 mg/day of
CENA713B2311
June-02
Exelon® (Rivastigmine) capsules in patients with
Parkinson’s disease dementia.
An open-label, 24-week extension to a 24-week
prospective, randomized, multicenter, double-blind,
placebo-controlled, parallel-group study of the efficacy,
DecemberCENA713B2311E1
tolerability and safety of 3-12 mg/day of Exelon®
02
(Rivastigmine) capsules in patients with Parkinson’s
Disease Dementia.
A randomized, double-blind, three period, cross-over
study of Ropinirole CR and Ropinirole IR Monotherapy
101468/168
February-03
in subjects with early phase Parkinson’s disease.
A phase III, randomized, double blind, placebocontrolled, parallel group study of six months treatment
with Ropinirole CR as adjunctive therapy in patients
SKYE-101468/169
March-03
with phase Parkinson’s disease who are not optimally
controlled on L-dopa.
A 24-week, multicenter, randomized, double-blind,
placebo-controlled study of the efficacy, tolerability and
DecemberE2020-E044-316
safety of Donepezil (Aricept) in Parkinson’s disease
02
patients with dementia.
An open-label extension study with REQUIP
September(Ropinirole) CR for subjects from studies 101468/165,
101468/248
03
101468/168 and 101468/169.
Feasibility study on the characteristics of Parkinson’s
disease symptoms for the planned phase III studies
/
February-04
with Sarizotan (EMR 62 225).
A 52-week multicenter, open label extension of the
safety, tolerability and efficacy of Donepezil (Aricept®)
E2020-E044-318
October-02
in Parkinson’s disease patients with dementia.
A long term, double-blind, randomized, parallel-group,
Carbidopa/Levodopa controlled, multi-center study to
evaluate the effect of STALEVO TM in patients with
CELC200A2401/2939107
May-04
Parkinson's disease who require initiation of Levodopa
therapy.
A double-blind, placebo controlled, multicenter,
multinational phase III study to evaluate the safety and
efficacy of Sarizotan HCl 1 mg b.i.d. in patients with
EMR 62225-019
July-04
Parkinson’s disease suffering from treatment
associated dyskinesias. PADDY-2
CV Barbara A. Pickut
Page 3/5
24
25
26
27
28
29
30
31
32
33
An open-label, multicenter, multinational phase III
follow-up study to investigate the long-term safety and
efficacy of Sarizotan HCl 1 mg b.i.d. in patients with
Parkinson’s disease suffering from treatmentassociated dyskinesias. PADDY-O
Identificatie van nieuwe genen en risicofactoren voor
de ziekte van Parkinson.
Ontwikkeling en evaluatie van een interprofessioneel
valpreventieprogramma voor Parkinson-patiënten.
Observational study to determine the incidence of newonset cardiac valvulopathy in patients treated with
Pergolide as second-line therapy for Parkinson’s
disease.
Long-term observation study of all patients treated with
Duodopa® for advanced Parkinson’s disease in
Belgium.
A phase III, double-blind, placebo-controlled,
randomized trial to determine the efficacy and safety of
a dose range of 50 to 100 mg/day of Safinamide, as
add-on therapy, in subjects with idiopathic Parkinson’s
disease with motor fluctuations, treated with a stable
dose of Levodopa and who may be receiving
concomitant treatment with stable doses of a dopamine
agonist, an Anticholinergics and/or Amantadine.
Safinamide in IPD with motor fluctuations, as add-on to
Levodopa: SETTLE.
A 76-week, prospective, open-label, multicenter study
to evaluate the long-term effect of Exelon® capsule
and transdermal patch on worsening of the underlying
motor symptoms of PD in patients with mild to
moderately severe dementia associated with
Parkinson’s disease (PDD).
A cognitive training program in Parkinson’s Disease
based on principles of brain plasticity.
Open-label trial to determine the long-term safety of
Safinamide in Parkinson’s disease patients.
Identificatie van genen en genetische risicofactoren
voor de ziekte van Parkinson.
CV Barbara A. Pickut
EMR 6225-030
February-05
41597
May-05
/
May-05
B4G-MC-B001
June-05
S187.4.002
May-07
27919
June-07
CENA713B2315
August-07
/
March-09
28850
July-09
/
November09
Page 4/5
SOCIETES

Member of the American Association of Public Health (1982)

Member of the American Association for World Health (1983)

Dutch Belgian Experimental and Clinical Neurochemistry Association (1992)

Member Flemish Neurological Association (Vlaamse Vereniging van Zenuwartsen)
(1995)

Flemish Workgroup Movement Disorders, officially recognized by the
Movement Disorders Society, 2010 (2006)

Member Movement Disorder Society (2007)
ADVISORY BOARDS
Participation in / member of the following Advisory Boards for:





Boehringer Ingelheim
GSK (GlaxoSmithKline)
Novartis
Solvay Pharmaceuticals
UCB
CV Barbara A. Pickut
Page 5/5